文献速递心力衰竭与心肌病

转甲状腺素蛋白淀粉样变心肌病结局试验中死亡获益的时机

Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis.
PubMed 文献 · J Am Coll Cardiol · 2025-09-25

该研究从ATTR-ACT、ATTRIBUTE-CM和HELIOS-B三项随机试验的Kaplan-Meier曲线提取死亡时间数据,用灵活参数生存模型估计瞬时HR。结果显示死亡曲线约在治疗后12-18个月开始分离,汇总模型证实获益延迟但逐渐增强,HR约在15个月(95%CI 10-19)降至0.80以下,三项试验间无显著差异。

要点

  • ATTR-CM治疗死亡获益延迟出现,约12-18个月曲线分离
  • 汇总模型显示获益随时间逐渐增强,HR约15个月降至0.80以下
  • 三项试验瞬时HR无显著差异,提示共同机制

核心结论

  • TTR稳定剂和沉默剂在ATTR-CM中带来延迟但一致的死亡获益,三项主要试验间无显著差异。

研究设计与样本

  • 从ATTR-ACT(tafamidis)、ATTRIBUTE-CM(acoramidis)和HELIOS-B(vutrisiran)三项随机试验的已发表Kaplan-Meier曲线提取死亡时间数据。
  • 使用灵活参数生存模型估计瞬时HR并评估时间变化治疗效果。

主要发现

  • 每项ATTR-CM试验的死亡曲线约在治疗开始后12至18个月开始分离。
  • 瞬时HR显示三项试验一致的时间变化治疗效果(P = 0.96),汇总模型证实获益延迟但逐渐增强(治疗效果P < 0.001;时间交互P < 0.001)。
  • 三项试验瞬时HR无显著差异,CI广泛重叠。
  • 估计死亡治疗效果HR在随机化后约15个月(95% CI: 10-19)降至0.80以下,并在整个随访期间持续增强。

临床怎么用

  • 临床应重视ATTR-CM早期启动治疗,并确保足够治疗时长以捕捉延迟的死亡获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapies for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including transthyretin (TTR) stabilizers and silencers, have demonstrated mortality benefit in 3 randomized trials. However, the timing of this benefit-often appearing delayed-has been debated and has broad implications for clinical use and trial design. OBJECTIVES: The purpose of this study was to evaluate the time course of mortality benefit with TTR stabilizers and silencers in ATTR-CM by estimating time-varying treatment effects across 3 randomized trials. METHODS: We extracted time-to-event mortality data from the published Kaplan-Meier curves of 3 ATTR-CM outcomes trials: ATTR-ACT (tafamidis), ATTRIBUTE-CM (acoramidis), and HELIOS-B (vutrisiran). Using flexible parametric survival models, we estimated instantaneous HRs and assessed the time-varying treatment effects across trials. RESULTS: Mortality curves in each ATTR-CM trial began to diverge between approximately 12 to 18 months after therapy initiation. Instantaneous HRs showed consistent time-varying treatment effects across trials (P = 0.96), with a pooled model confirming a delayed but progressively strengthening benefit (P for treatment effect < 0.001; P for time interaction < 0.001). No significant differences were found between the 3 trials in the instantaneous HRs with widely overlapping CIs. We estimate that the treatment effect HR for mortality drops below 0.80 around 15 months (95% CI: 10-19) after randomization and continues to strengthen throughout follow-up. CONCLUSIONS: TTR silencers and stabilizers in ATTR-CM confer a delayed but consistent mortality benefit with no significant differences observed between the 3 major trials. This uniform pattern may reflect a shared mechanism of action-reducing new amyloid deposition rather than reversing established disease-and may underscore the importance of early treatment initiation and adequate trial duration to capture delayed mortality effects. (ATTR-ACT [Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy; NCT01994889]; ATTRIBUTE-CM [Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy; NCT03860935]; and HELIOS-B [A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149]).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Claggett BL, Fontana M, Vaduganathan M, et al. Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis. J Am Coll Cardiol. 2025. PMID: 41225306. doi:10.1016/j.jacc.2025.09.1512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。